LONG-TERM CARDIORESPIRATORY EFFECTS OF AMELIORATION OF RENAL ANEMIA BY ERYTHROPOIETIN

The long-term cardiorespiratory effects of recombinant human erythropoietin treatment were investigated in ten haemodialysis patients by means of maximum exercise testing, lung function tests, echocardiography, chest X-ray, and rheological assessment over 12 months. There were significant rises in exercise time (mean [SD] 13·2 [5·5] to 20·0 [6·2] min), maximum oxygen consumption (19·1 [7·0] to 25·0 [6·7] ml.min-1.kg-1), and anaerobic threshold (11·7 [3·6] to 15·4 [4·8] ml.min-1.kg-1) after 2 months of erythropoietin treatment. The improvements were maintained but not augmented on repeat testing after 4, 8, and 12 months of therapy. Carbon monoxide treatment rose from 15·5 (2·9) to 18·6 (3·7) ml.min-1.mm Hg-1. There was a substantial reduction in exercise-induced cardiac ischaemia (eight patients had significant ST segment depression before erythropoietin, only one after 2 months' treatment, and none after 12 months' treatment), despite a significant rise in whole blood viscosity. Left ventricular mass, as estimated by echocardiography, progressively decreased from 354 (169) g to 251 (95) g after 12 months' treatment, and four patients showed a reduction in cardiothoracic ratio on chest X-ray. © 1990.